Recurring concern

Failure to ensure paramedics have required emergency medicines for pre-hospital care

Pin Get email alerts Request correction

First reported 20 Dec 2019•Latest report 10 Apr 2026

Definition

What this concern includes

Includes failures of dedicated pre-hospital medication-provision controls, including decisions about carrying, authorising, supplying, or enabling paramedics to administer required emergency medicines.

Not included

  • Excludes medication-prescribing, dispensing or administration failures occurring after hospital admission unless they are specifically part of pre-hospital medication provision.
  • Excludes generic ambulance staffing, training or equipment deficiencies unless they directly prevent paramedics from carrying or administering a required emergency medicine.
  • Excludes clinical decisions about which medicine is appropriate where access or authorisation to provide the medicine is not deficient.
  • Excludes medicines and treatments unrelated to emergency pre-hospital care.
Reports
8

Distinct published reports

Individual concerns
8

A report can raise multiple concerns

Date range
2019–2026

First to latest report issue date

Stated actions
18

Described in published responses

Reports over time

Reports over time

Reports about this concern issued each year.

* 2026 is projected from reports observed to 7 Sep 2026.

Most frequent recipients

Most frequent recipients

Reports about this concern sent to each recipient.

Welsh Ambulance Services NHS Trust2
West Midlands Ambulance Service University NHS Foundation Trust2
Department of Health and Social Care1
East Midlands Ambulance Service NHS Trust1
Home Office1
Joint Royal Colleges Ambulance Liaison Committee1
Kettering General Hospital1
Medicines and Healthcare products Regulatory Agency1
NHS England1
Office of the Chief Coroner1
South East Coast Ambulance Service NHS Foundation Trust1

Concerns and responses across reports

Only concerns grouped under this recurring concern are included. Select any concern, action or position to view the source wording.

  1. Shropshire, Telford and Wrekin

    AI-generated summary

    Wayne AUSTIN · Prevention of Future Deaths report

    This summary was generated using AI from the published report. Please read the original report for the complete account.

    Report summary

    Wayne Austin became unwell and collapsed at Shrewsbury Probation office on 10 October 2024 after reporting that he had consumed cider; paramedics were subsequently informed that he had consumed crack cocaine. He was treated with CPR, advanced life support and Naloxone, transferred to hospital, and died as a result of combined buprenorphine and alcohol toxicity. Concerns included difficulty locating and applying the appropriate Naloxone guidance, the practical difficulty of complying with dosing guidelines during cardiac arrest, and the number of Naloxone vials carried by ambulances.

    Read the report on judiciary.uk

    Source evidence

    How this individual concern was interpreted

    PFD Monitor created a concise, searchable interpretation from the report wording shown below.

    PFD Monitor interpretation

    Insufficient Naloxone stock carried per ambulance for opioid-related cardiac arrest

    Wider context from the report

    “(3) WMAS ambulances only carry a box of 10 Naloxone 400mg vials per ambulance which means that one ambulance attending a situation such as Wayne’s would be insufficient to deal with the circumstances, as would two ambulances. It would mean that three ambulances are required to comply with cardiac arrest (where opioid toxicity is the likely cause). ”

    Source location

    Wayne AUSTIN · Prevention of Future Deaths report
    Page 2 · concerns

    Open source report

    Source evidence

    How this respondent action was interpreted

    PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

    PFD Monitor interpretation

    Complete formal clinical reviews of ambulance Naloxone Hydrochloride quantities and confirm the current ten-ampoule load list remains appropriate.

    Verbatim wording from the response

    “WMAS has undertaken formal clinical review of this issue. An initial review of Naloxone Hydrochloride quantities was completed in May 2025 by the WMAS Consultant Paramedic for Emergency Care, followed by a further review in September 2025 by the senior clinical team. The latter specifically considering the cardiac arrest guidance where opioid overdose is suspected. The consensus from the latest review was that the current Naloxone Hydrochloride quantities carried on the WMAS Load List were appropriate.”

    Source location

    Response from West Midlands Ambulance Service
    Page 4 · response
    Published 17 April 2026

    Open published response

    Source evidence

    How this respondent action was interpreted

    PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

    PFD Monitor interpretation

    Review the naloxone monograph.

    Verbatim wording from the response

    “We are currently working on standardising all drug monographs through our Medicines Governance Group to ensure that all medicines monographs within JRCALC meet legal, regulatory, and good practice requirements. The naloxone monograph is currently under review, and we have shared the matters of concern with the lead person for the drug monograph and the JRCALC committee who have approved changes in response to your concerns.”

    Source location

    Response from Association of Ambulance Chief Executives (on behalf of the Joint Royal Colleges Ambulance Liaison Committee)
    Page 1 · response
    Published 17 April 2026

    Open published response

    Source evidence

    How this respondent action was interpreted

    PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

    PFD Monitor interpretation

    Approve changes to the naloxone monograph in response to the concerns raised.

    Verbatim wording from the response

    “We are currently working on standardising all drug monographs through our Medicines Governance Group to ensure that all medicines monographs within JRCALC meet legal, regulatory, and good practice requirements. The naloxone monograph is currently under review, and we have shared the matters of concern with the lead person for the drug monograph and the JRCALC committee who have approved changes in response to your concerns.”

    Source location

    Response from Association of Ambulance Chief Executives (on behalf of the Joint Royal Colleges Ambulance Liaison Committee)
    Page 1 · response
    Published 17 April 2026

    Open published response

    Source evidence

    How this respondent action was interpreted

    PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

    PFD Monitor interpretation

    Remove naloxone use during cardiac arrest from the JRCALC guidance.

    Verbatim wording from the response

    “The JRCALC committee has approved the removal of the use of naloxone during cardiac arrest. The evidence that naloxone improves survival once cardiac arrest has occurred is limited. Furthermore, it may distract the attending clinicians from more important tasks such as early defibrillation, high quality chest compressions and effective ventilation. The use of naloxone will remain indicated for the reversal of acute opioid or opiate toxicity for respiratory arrest or respiratory depression; this is detailed in several of our clinical guidelines. We have also contacted the UK National Poisons Information Service to discuss the recommended cardiac arrest management for opioid poisoning.”

    Source location

    Response from Association of Ambulance Chief Executives (on behalf of the Joint Royal Colleges Ambulance Liaison Committee)
    Page 2 · response
    Published 17 April 2026

    Open published response

    Source evidence

    How this respondent action was interpreted

    PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

    PFD Monitor interpretation

    Have the agreed naloxone changes reviewed by the national ambulance service medical directors group.

    Verbatim wording from the response

    “The changes agreed to the use of naloxone by the JRCALC committee will be reviewed by the national ambulance service medical directors group (NASMeD) and, subject to approval, will subsequently be introduced into ambulance service clinical practice guidelines.”

    Source location

    Response from Association of Ambulance Chief Executives (on behalf of the Joint Royal Colleges Ambulance Liaison Committee)
    Page 2 · response
    Published 17 April 2026

    Open published response

    Source evidence

    How this respondent action was interpreted

    PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

    PFD Monitor interpretation

    Introduce the approved naloxone changes into ambulance service clinical practice guidelines, subject to approval.

    Verbatim wording from the response

    “The changes agreed to the use of naloxone by the JRCALC committee will be reviewed by the national ambulance service medical directors group (NASMeD) and, subject to approval, will subsequently be introduced into ambulance service clinical practice guidelines.”

    Source location

    Response from Association of Ambulance Chief Executives (on behalf of the Joint Royal Colleges Ambulance Liaison Committee)
    Page 2 · response
    Published 17 April 2026

    Open published response

    Source evidence

    How this respondent position was interpreted

    PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

    PFD Monitor interpretation

    The recommended maximum naloxone stock is not a realistic operational benchmark because benefit during established cardiac arrest is limited and uncertain.

    Verbatim wording from the response

    “WMAS acknowledges that, based on the JRCALC cardiac arrest guidance, where opioid toxicity is considered the likely cause, the cumulative Naloxone Hydrochloride dose required would exceed the stock carried on a single ambulance, and a second ambulance. However, WMAS does not consider this to represent a realistic or operationally appropriate benchmark against which the WMAS Drug Load List should be assessed.”

    Source location

    Response from West Midlands Ambulance Service
    Page 4 · response
    Published 17 April 2026

    Open published response

    Source evidence

    How this respondent position was interpreted

    PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

    PFD Monitor interpretation

    Increasing naloxone stock would impose significant logistical and financial burdens disproportionate to its limited and uncertain cardiac-arrest benefit.

    Verbatim wording from the response

    “There are also practical considerations related to medicine supply resilience. Naloxone Hydrochloride has previously been subject to national supply constraints. Increasing carriage to 25 ampoules per ambulance, alongside maintaining sufficient reserve stock to support fleet-wide replenishment, would present a significant logistical and financial burden. When weighed against the limited and uncertain benefit of Naloxone Hydrochloride in cardiac arrest, this does not represent a proportionate risk-benefit or cost-benefit intervention.”

    Source location

    Response from West Midlands Ambulance Service
    Page 4 · response
    Published 17 April 2026

    Open published response

    Source evidence

    How this respondent position was interpreted

    PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

    PFD Monitor interpretation

    The current load-list quantity of 10 naloxone ampoules per ambulance is considered appropriate for respiratory arrest or respiratory depression.

    Verbatim wording from the response

    “WMAS has undertaken formal clinical review of this issue. An initial review of Naloxone Hydrochloride quantities was completed in May 2025 by the WMAS Consultant Paramedic for Emergency Care, followed by a further review in September 2025 by the senior clinical team. The latter specifically considering the cardiac arrest guidance where opioid overdose is suspected. The consensus from the latest review was that the current Naloxone Hydrochloride quantities carried on the WMAS Load List were appropriate.”

    Source location

    Response from West Midlands Ambulance Service
    Page 4 · response
    Published 17 April 2026

    Open published response

    Source evidence

    How this respondent position was interpreted

    PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

    PFD Monitor interpretation

    Increasing naloxone stocks is unnecessary because naloxone will no longer be recommended during opioid-related cardiac arrest.

    Verbatim wording from the response

    “3) WMAS ambulances only carry a box of 10 Naloxone 400mg vials per ambulance which means that one ambulance attending a situation such as Wayne’s would be insufficient to deal with the circumstances, as would two ambulances. It would mean that three ambulances are required to comply with cardiac arrest (where opioid toxicity is the likely cause).”

    Source location

    Response from Association of Ambulance Chief Executives (on behalf of the Joint Royal Colleges Ambulance Liaison Committee)
    Page 2 · response
    Published 17 April 2026

    Open published response
  2. West Sussex, Brighton and Hove

    AI-generated summary

    Joel Phillip COLK · Prevention of Future Deaths report

    This summary was generated using AI from the published report. Please read the original report for the complete account.

    Report summary

    Joel Phillip Colk called 999 after ingesting at least 50g of a substance and was attended by an ambulance after the call was upgraded from category 3 to category 2. He was in cardiac arrest on attendance and died at home on 2 October 2023. The concerns include that NHS Pathways did not differentiate overdoses by substance, amount, timing or patient weight, and did not reflect the time-sensitive treatment required for this ingestion; ambulances also did not carry the antidote in the area described.

    Read the report on judiciary.uk

    Source evidence

    How this individual concern was interpreted

    PFD Monitor created a concise, searchable interpretation from the report wording shown below.

    PFD Monitor interpretation

    Unavailability of methylene blue on ambulances for relevant chemical ingestions

    Wider context from the report

    “The Court heard that when a call is made to 999 that the call is categorised using NHS Pathways and that all overdoses would be in the same classification resulting in the same disposition and response category. The system does not differentiate between types of, severity of or the drugs/chemicals reported as being the cause of the overdose. The system also does not differentiate call classification taking into account the amount reported as ingested, the timing of ingestion or the patient's weight. The Court heard that all of these factors can impact on the time in which care needs to be rendered to prevent death. The example given to the Court was that someone who had taken a relatively small paracetamol that would be unlikely to cause harm would, using Pathways, have the same resultant disposition as someone who had ingested a significant amount of a known lethal chemical. Secondly, the Court heard that in the case of ████████ ingestion that treatment is only effective if medications are administered before the patient suffers a cardiac arrest. This likely will occur incredibly rapidly and is a known effect of the chemical. The Pathways system does not reflect the time sensitive nature of an effective response when it is known that ████████ has been ingested and would not create a higher disposition requiring more urgent attendance than category 3. The Court was also told that clinicians do not carry on any Ambulances within South East Coast Ambulance Service NHS Foundation Trust Methylene Blue which is the antidote to ████████ ingestion as this is not within national guidance. I heard that in some areas there are ongoing trials for some areas that this is on board vehicles within the HART (Hazardous Area Response Team). Therefore in this area the treatment is only available when a patient reaches an acute hospital with an A&E department and the evidence was that often patients enter cardiac arrest before this occurs. ”

    Source location

    Joel Phillip COLK · Prevention of Future Deaths report
    Page 2 · concerns

    Open source report

    Source evidence

    How this respondent action was interpreted

    PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

    PFD Monitor interpretation

    Remain engaged in national ambulance-service discussions about methylene blue for sodium nitrite poisoning and review emerging authoritative recommendations.

    Verbatim wording from the response

    “Ongoing National Discussions”

    Source location

    Response from SECAmb
    Page 4 · response
    Published 13 November 2024

    Open published response

    Source evidence

    How this respondent action was interpreted

    PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

    PFD Monitor interpretation

    Continuously review the medication formulary against emerging guidance and new evidence to support patient safety.

    Verbatim wording from the response

    “In conclusion, SECAmb remains committed to delivering the highest standard of pre-hospital care within the framework of evidence-based clinical practice. We will continuously review our medication formulary in line with emerging guidance and new evidence. At present, and in accordance with current national recommendations, equipping all front-line ambulances with methylene blue and specialist diagnostic tools is neither clinically feasible nor cost-effective. Nevertheless, we will continue to monitor evolving guidance and, where appropriate, modify our protocols to maintain patient safety and optimise outcomes.”

    Source location

    Response from SECAmb
    Page 5 · response
    Published 13 November 2024

    Open published response

    Source evidence

    How this respondent position was interpreted

    PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

    PFD Monitor interpretation

    Equipping all frontline ambulances with methylene blue and specialist diagnostic equipment is not clinically feasible or cost-effective because of diagnostic, logistical and resource constraints.

    Verbatim wording from the response

    “████████ poisoning causes methaemoglobinaemia, which can only be reliably diagnosed using specialised diagnostic equipment (e.g., Masimo Rainbow SET sensors). In a pre-hospital context, the accurate identification of sodium nitrite ingestion is complicated by non-specific presentations and the unlikelihood of having immediate access to this specialist equipment on every frontline vehicle. Consequently, the administration of methylene blue in the pre-hospital setting poses significant diagnostic and logistical challenges, especially given the low incidence of confirmed sodium nitrite poisonings.”

    Source location

    Response from SECAmb
    Page 4 · response
    Published 13 November 2024

    Open published response

    Source evidence

    How this respondent position was interpreted

    PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

    PFD Monitor interpretation

    Rapid hospital transfer and advanced cardiac life support remain the most appropriate existing response because definitive treatment is available at hospital.

    Verbatim wording from the response

    “Although certain regions are trialling the use of Hazardous Area Response Teams (HART) to carry methylene blue, these teams are designed for high-risk environments. SECAmb’s HART operates from two bases (Ashford and Crawley), but their geographic reach and the unpredictable nature of ████████ poisonings do not guarantee they would always be the initial or timely responders to these cases. In many instances, rapid transfer to hospital—where comprehensive evaluation and definitive treatment (such as intubation, ventilation, inotropic support, or exchange transfusion) can be provided—remains the most pragmatic approach.”

    Source location

    Response from SECAmb
    Page 4 · response
    Published 13 November 2024

    Open published response

    Source evidence

    How this respondent position was interpreted

    PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

    PFD Monitor interpretation

    Mandating ambulance services to carry Methylene Blue is outside NHS England’s remit because medication carriage is an operational matter for individual trusts.

    Verbatim wording from the response

    “The carrying of particular medication by ambulance services is an operational issue and is up to individual ambulance trusts; NHS England does not mandate such issues. NHS England is aware of a small number of ambulance specialist units who carry Methylene Blue. This antidote is carried by specialist clinical teams for administration in cases of moderate/severe ████████ poisoning which can be measured through an exhaled breath monitor. Clinical feedback suggests it is likely Methylene Blue would not be used except for severe cases or where there is a long journey time to definitive care.”

    Source location

    Response from NHS England
    Page 4 · response
    Published 13 November 2024

    Open published response

    Source evidence

    How this respondent position was interpreted

    PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

    PFD Monitor interpretation

    Individual ambulance trusts are responsible for deciding whether to carry Methylene Blue; NHS England does not mandate this operational arrangement.

    Verbatim wording from the response

    “The carrying of particular medication by ambulance services is an operational issue and is up to individual ambulance trusts; NHS England does not mandate such issues. NHS England is aware of a small number of ambulance specialist units who carry Methylene Blue. This antidote is carried by specialist clinical teams for administration in cases of moderate/severe ████████ poisoning which can be measured through an exhaled breath monitor. Clinical feedback suggests it is likely Methylene Blue would not be used except for severe cases or where there is a long journey time to definitive care.”

    Source location

    Response from NHS England
    Page 4 · response
    Published 13 November 2024

    Open published response
  3. Northamptonshire

    AI-generated summary

    Harry Peter DUNN · Prevention of Future Deaths report

    This summary was generated using AI from the published report. Please read the original report for the complete account.

    Report summary

    Harry Peter Dunn, aged 19, died shortly after arriving at hospital following a head-on collision between his motorcycle and a car on 27 August 2019. The report raises concern that paramedics cannot access nasal or buccal analgesics that may assist with potentially lifesaving pre-hospital treatment or faster patient extraction when time is critical.

    Read the report on judiciary.uk

    Source evidence

    How this individual concern was interpreted

    PFD Monitor created a concise, searchable interpretation from the report wording shown below.

    PFD Monitor interpretation

    Unavailability of nasal or buccal analgesics to paramedics

    Wider context from the report

    “(1) As a result of the collision Mr Dunn landed in a prone position (on his front). In order for him to be treated by the pre hospital team he had to be moved out of this position to give ready access to his injuries. This necessitated the administration of analgesia. However, due to his positioning and the location of his injuries in conjunction with the extent of blood loss intravenous analgesics could not be administered. (2) Due to the experience level and qualifications of the pre hospital team in attendance, which included a Consultant Anaesthetist, an alternative form of analgesia, namely nasal morphine could be administered. (3) However, evidence was heard at the inquest that had the first attending team been a paramedic team they could not have administered this potentially lifesaving treatment as analgesia’s which can be delivered either nasally or buccally (via the cheek) are not presently available to paramedics despite being available to UK military personnel and mountain rescue teams. (4) I am concerned that the unavailability of such analgesics to paramedics to assist them to deliver potentially life saving pre hospital treatments or to enable a faster extraction of a patient where time is of the essence for medical treatment reflects a risk of deaths into the future. ”

    Source location

    Harry Peter DUNN · Prevention of Future Deaths report
    Page 2 · concerns

    Open source report

    Source evidence

    How this respondent action was interpreted

    PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

    PFD Monitor interpretation

    Take account of concerns when agreeing next steps with NHS England on expanding medicines supply, administration and prescribing responsibilities.

    Verbatim wording from the response

    “Please be assured that we will take account of your concerns when agreeing the next steps in our joint work programme with NHSE regarding expanding supply, administration and prescribing of medicines responsibilities for regulated healthcare professionals.”

    Source location

    Response-from-DHSC
    Page 2 · response
    Published 7 August 2024

    Open published response
  4. Swansea and Neath Port Talbot

    AI-generated summary

    STEFAN WALKER · Prevention of Future Deaths report

    This summary was generated using AI from the published report. Please read the original report for the complete account.

    Report summary

    STEFAN WALKER was a detained patient receiving inpatient psychiatric treatment when he became unresponsive in his room on 29 June 2020 after concerns that he had consumed illicit substances and was physically unwell. The inquest concluded that his death was drug related, with the medical cause given as buprenorphine and flualprazolam intoxication and cardiac enlargement. The principal concern was that paramedics did not carry flumazenil, which might be needed in acute circumstances involving certain benzodiazepines.

    Read the report on judiciary.uk

    Source evidence

    How this individual concern was interpreted

    PFD Monitor created a concise, searchable interpretation from the report wording shown below.

    PFD Monitor interpretation

    Failure of paramedics and ambulance crew to carry flumazenil for acute emergencies

    Wider context from the report

    “(1) I was told that paramedics and ambulance crew do not carry flumazenil (but often do carry naloxone). The availability of flumazenil was hampered in this case because STEFAN was on an acute psychiatric ward where the said antagonist was being kept and could be prescribed by the ward pharmacist and administered by the doctors (with the support paramedics when they arrived). (2) I am concerned that there may be other acute circumstances when the use of this particular antagonist (flumazenil) could make a difference (say in the case of the collapse of person on the street or otherwise in the community) but will not be available since paramedics do not it. (3) I and the jury heard no evidence as to why naloxone is carried, but other antagonists (such as flumazenil) not. ”

    Source location

    STEFAN WALKER · Prevention of Future Deaths report
    Page 2 · concerns

    Open source report

    Source evidence

    How this respondent action was interpreted

    PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

    PFD Monitor interpretation

    Authorise trained paramedics to carry and use flumazenil under a patient group directive only to reverse benzodiazepines they administered.

    Verbatim wording from the response

    “Some of our Welsh Ambulance Service paramedics do carry flumazenil and may utilise it under a patient group directive (PGD) authority. But this use is specifically only for the emergency reversal of benzodiazepines which they have administered, so this only applies to paramedics who are trained and authorised to use advanced sedative pain-relieving drug options. These paramedics however can (and should) only use flumazenil in this specific context, and the PGD is explicit that it should not be used in the context of other suspected benzodiazepine overdose for the reasons outlined above.”

    Source location

    Response from Welsh Ambulance Service
    Page 2 · response
    Published 25 June 2024

    Open published response

    Source evidence

    How this respondent position was interpreted

    PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

    PFD Monitor interpretation

    Flumazenil should not be carried for suspected benzodiazepine overdose because its use is hazardous and contrary to current clinical guidance.

    Verbatim wording from the response

    “There are very robust clinical reasons as to why flumazenil cannot and should not be considered in the same way. While flumazenil does reverse the effects of benzodiazepines, its use for overdosage of benzodiazepines (and in particular overdose in the context of multiple drugs including benzodiazepines) is controversial and potentially very hazardous.”

    Source location

    Response from Welsh Ambulance Service
    Page 2 · response
    Published 25 June 2024

    Open published response

    Source evidence

    How this respondent position was interpreted

    PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

    PFD Monitor interpretation

    Use of flumazenil outside its licensed indication cannot legally be authorised for paramedic use.

    Verbatim wording from the response

    “The UK licenced indication for flumazenil is the “reversal of sedative effects of benzodiazepines in anaesthesia and clinical procedures”. Any use in other circumstances would be outside of the scope of the UK product licence and would not be something we could legally authorise for paramedic use.”

    Source location

    Response from Welsh Ambulance Service
    Page 2 · response
    Published 25 June 2024

    Open published response

    Source evidence

    How this respondent position was interpreted

    PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

    PFD Monitor interpretation

    Existing advanced airway techniques and supportive care strategies are considered more appropriate for managing benzodiazepine overdose.

    Verbatim wording from the response

    “Hopefully the explanation I have provided above will reassure you that flumazenil should not be used in this context based on all current clinical guidelines. Ambulance personnel are trained in advanced airway techniques and other supportive care strategies which are more appropriate for the management of benzodiazepine overdose.”

    Source location

    Response from Welsh Ambulance Service
    Page 3 · response
    Published 25 June 2024

    Open published response
  5. North West Wales

    AI-generated summary

    Jane Walker · Prevention of Future Deaths report

    This summary was generated using AI from the published report. Please read the original report for the complete account.

    Report summary

    Jane Walker was a passenger on a rigid inflatable boat involved in a collision with a jet ski on the Menai Straits. She suffered significant internal injuries, was treated by paramedics and later died in hospital. The principal concern was that paramedics could not administer faster-acting alternative analgesics, such as mucosal fentanyl, because of controlled drug legislation, potentially affecting patients requiring immediate pain relief.

    Read the report on judiciary.uk

    Source evidence

    How this individual concern was interpreted

    PFD Monitor created a concise, searchable interpretation from the report wording shown below.

    PFD Monitor interpretation

    Unavailability of rapid analgesics to paramedics for immediate pre-hospital pain relief

    Wider context from the report

    “Evidence was heard at the Inquest that there are alternative analgesics which can be administered much more quickly, have a much quicker impact and can be easier to remove when required. Example of such is mucosal fentanyl lozenge. This can be administered by placing the lozenge (on a stick) into the patient’s mouth, which takes effect very quickly and which can be removed quickly if required. It can be considered a safe and rapid method of delivering pre-hospital analgesia and is used by the military. It is not, however, available to paramedics. I am concerned that the unavailability of such analgesics to paramedics (in England as well as Wales) to assist patients who require immediate pain relief in the context of it reducing stress on the body, providing easier and potentially faster extrication and patient handling, and improving breathing, where time is of the essence for medical treatment, to reflect a risk of deaths into the future. Pursuant to controlled drug legislation paramedics are not currently permitted to administer such analgesics. Whilst matters of health are devolved to Wales, controlled drug legislation in this context is not a devolved matter to Wales, hence this Report to the Home Secretary. I am aware that The Medicines Act 1968 and/or other controlled drug legislation would require amendment to allow paramedics to administer such analgesia. ”

    Source location

    Jane Walker · Prevention of Future Deaths report
    Page 2 · concerns

    Open source report
  6. Northamptonshire

    AI-generated summary

    Alfie Stone · Prevention of Future Deaths report

    This summary was generated using AI from the published report. Please read the original report for the complete account.

    Report summary

    Alfie Stone, aged 12, died after prolonged seizures, status epilepticus, hypoxia and multiple organ failure following admission to hospital. Concerns included paramedics’ lack of training in buccal midazolam, inadequate oxygenation, no suction attempt, and insufficient evidence of training following an earlier Serious Incident Report.

    Read the report on judiciary.uk

    Source evidence

    How this individual concern was interpreted

    PFD Monitor created a concise, searchable interpretation from the report wording shown below.

    PFD Monitor interpretation

    Failure to accept recommendations to carry and administer buccal midazolam when necessary

    Wider context from the report

    “(5) East Midlands Ambulance Service were not accepting the recommendations 3 within the report to carry and administer Buccal Midazolam when necessary. ”

    Source location

    Alfie Stone · Prevention of Future Deaths report
    Page 1 · concerns

    Open source report

    Source evidence

    How this respondent action was interpreted

    PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

    PFD Monitor interpretation

    Assess the impact of adding buccal midazolam to the medicines formulary, including effectiveness, access, storage and alternative treatments.

    Verbatim wording from the response

    “Following a review of the concerns raised in the PFD notice received on 19 January 2022, the concerns relating specifically to midazolam will be discussed at the Medicines Governance Group in February 2022 to assess the impact of adding buccal midazolam to the EMAS medicines formulary. The impact will consider treatment effectiveness, timely access to midazolam on Trust ambulances as it will need to be securely stored in a cabinet only accessible by controlled key access and it may take longer to access in an emergency (due to this being a Schedule 3 controlled drug within the Misuse of Drugs Regulations 2001) and alternative treatments.”

    Source location

    2022-0013-Response-from-East-Midlands-Ambulance-Service_Published
    Page 2 · response
    Published 20 January 2022

    Open published response

    Source evidence

    How this respondent action was interpreted

    PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

    PFD Monitor interpretation

    Develop an action plan covering training for staff who access or administer buccal midazolam, including patient-held medication.

    Verbatim wording from the response

    “The Medicines Governance Group will develop an action plan that will consider training for all staff who would access and administer buccal midazolam in an emergency, as well as staff who may need to access and administer buccal midazolam not supplied by EMAS but held at the patient’s home or other facility.”

    Source location

    2022-0013-Response-from-East-Midlands-Ambulance-Service_Published
    Page 2 · response
    Published 20 January 2022

    Open published response

    Source evidence

    How this respondent action was interpreted

    PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

    PFD Monitor interpretation

    Add permission to administer buccal midazolam to the Scope of Practice Policy for paramedic staff.

    Verbatim wording from the response

    “this (where family/carer are unable to do so) according to JRCALC buccal midazolam guidance. This is a recent addition to EMAS JRCALC guidance which is available to EMAS staff to access as an ‘App’ on their phone, iPad or other electronic device. It is to be added to the EMAS Scope of Practice Policy to ensure clarity for paramedic staff that they can administer within EMAS guidance.”

    Source location

    2022-0013-Response-from-East-Midlands-Ambulance-Service_Published
    Page 2 · response
    Published 20 January 2022

    Open published response

    Source evidence

    How this respondent action was interpreted

    PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

    PFD Monitor interpretation

    Begin the governance and legal process for transitioning from the current anticonvulsant medication to buccal midazolam.

    Verbatim wording from the response

    “Buccal Midazolam is on the agenda for the February Medicines Management Group, which is attended by senior Medical, Pharmacy and Quality leads. The intended timeline will be to start the process in April 2022, on the transition from our current anti-convulsant medication to Buccal Midazolam along with the legal processes we need to adopt to carry out this transition within the legal frameworks for this medication. The HM Coroner will be kept updated throughout this process.”

    Source location

    2022-0013-Response-from-East-Midlands-Ambulance-Service_Published
    Page 2 · response
    Published 20 January 2022

    Open published response

    Source evidence

    How this respondent action was interpreted

    PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

    PFD Monitor interpretation

    Develop and present a business case for moving to buccal midazolam, using gathered data and liaison with other ambulance trusts.

    Verbatim wording from the response

    “As in point 1 above, EMAS provides rectal diazepam (and intravenous diazepam) for the treatment of convulsions and both are recognised treatments within the UK ambulance service clinical practice guidelines, developed by JRCALC, and within NICE guidance. Due to the discontinuation of diazepam rectal tubes 2.5mg, EMAS made a recommendation at its Medicines Governance Group in November 2021 to gather data and build a business case regarding a move to buccal midazolam, liaising with other Ambulance Trusts.”

    Source location

    2022-0013-Response-from-East-Midlands-Ambulance-Service_Published
    Page 3 · response
    Published 20 January 2022

    Open published response

    Source evidence

    How this respondent position was interpreted

    PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

    PFD Monitor interpretation

    No audit of buccal midazolam training was required because it was not in the medicines formulary at the time.

    Verbatim wording from the response

    “Recommendation 3 of the Kettering report states: “EMAS should audit training and competencies of first responders in administration of buccal midazolam in children experiencing prolonged seizures in line with Joint Royal Colleges Ambulance Liaison Committee (JRCALC) guidance”.”

    Source location

    2022-0013-Response-from-East-Midlands-Ambulance-Service_Published
    Page 4 · response
    Published 20 January 2022

    Open published response
  7. Warwickshire

    AI-generated summary

    Ashley WALKER · Prevention of Future Deaths report

    This summary was generated using AI from the published report. Please read the original report for the complete account.

    Report summary

    Ashley WALKER ingested a substance and was treated by an ambulance crew, who left after being told the scene was hazardous; he was left unattended for 45 minutes and was not breathing when extricated. The concerns included a communication error about the substance involved and the absence of an effective antidote on the ambulance.

    Read the report on judiciary.uk

    Source evidence

    How this individual concern was interpreted

    PFD Monitor created a concise, searchable interpretation from the report wording shown below.

    PFD Monitor interpretation

    Unavailability of an effective antidote on ambulances

    Wider context from the report

    “(2) ████████ toxicity is a recognised method of suicide and I heard evidence from a WMAS staff member that there is an effective antidote (methylene blue) but this was not available on the ambulance. ”

    Source location

    Ashley WALKER · Prevention of Future Deaths report
    Page 1 · concerns

    Open source report

    Source evidence

    How this respondent action was interpreted

    PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

    PFD Monitor interpretation

    Review whether HART paramedics can carry and administer methylene blue for sodium nitrate ingestion cases.

    Verbatim wording from the response

    “Response We are currently reviewing whether it would be feasible for our Hazardous Area Response Team (HART) paramedics to carry and administer methylene blue along with other medications to clinically manage cases where there has been chemical ingestion of sodium nitrate. The Lead Paramedic for the Trust has raised this nationally with the National Ambulance Resilience Unit (NARU) clinical sub-group, with a view to making this standard practice nationally.”

    Source location

    Response-from-West-Midlands-Ambulance-Service
    Page 1 · response
    Published 8 February 2020

    Open published response

    Source evidence

    How this respondent action was interpreted

    PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

    PFD Monitor interpretation

    Raise nationally with the NARU clinical subgroup the proposal to make methylene blue availability standard practice.

    Verbatim wording from the response

    “Response We are currently reviewing whether it would be feasible for our Hazardous Area Response Team (HART) paramedics to carry and administer methylene blue along with other medications to clinically manage cases where there has been chemical ingestion of sodium nitrate. The Lead Paramedic for the Trust has raised this nationally with the National Ambulance Resilience Unit (NARU) clinical sub-group, with a view to making this standard practice nationally.”

    Source location

    Response-from-West-Midlands-Ambulance-Service
    Page 1 · response
    Published 8 February 2020

    Open published response
  8. North Wales (East and Central)

    AI-generated summary

    Samantha Brousas · Prevention of Future Deaths report

    This summary was generated using AI from the published report. Please read the original report for the complete account.

    Report summary

    Samantha Brousas became critically ill with suspected sepsis and was taken to hospital, where she was diagnosed with septic shock secondary to pneumonia and died from a naturally occurring infection. The report identified concerns about the absence of a pre-alert to the emergency department, the inability of paramedics to administer intravenous antibiotics, and the lack of a clear process for escalating concerns about delayed admission.

    Read the report on judiciary.uk

    Source evidence

    How this individual concern was interpreted

    PFD Monitor created a concise, searchable interpretation from the report wording shown below.

    PFD Monitor interpretation

    Unavailability of intravenous antibiotic administration by ambulance paramedics when emergency department admission is delayed

    Wider context from the report

    “(2) I heard evidence during the course of the inquest that the first line treatment for sepsis was the administration of anti-biotics within an hour of arrival at a hospital consistent with the SEPSIS SIX and NICE guidelines. I also heard evidence that it was currently beyond the scope of the practice of WAST paramedics to administer antibiotics intravenously in an ambulance. Given the importance of the role of the Paramedic in the early diagnosis of Sepsis my concern is that when a patient is unable to be admitted into the emergency department in similar situations as the deceased, the absence of the administration of antibiotics increases the mortality risk of such patients which could be addressed by exemptions and local organisational level policies and procedures. ”

    Source location

    Samantha Brousas · Prevention of Future Deaths report
    Page 1 · concerns

    Open source report

    Source evidence

    How this respondent action was interpreted

    PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

    PFD Monitor interpretation

    Conduct the PhRASe feasibility study, including paramedic screening, randomisation, blood-culture collection and intravenous antibiotic administration, and complete anonymised follow-up analysis.

    Verbatim wording from the response

    “The PhRASe (Prehospital Recognition and Antibiotics for 999 patients with severe Sepsis) study was designed to determine if it was feasible for Trust paramedics to select and screen eligible patients, then randomise them to usual care or intervention (blood culture collection and administration of IV antibiotics). The main purpose of the study was to gather evidence, to inform the feasibility of a definitive study that could examine the effectiveness of prehospital antibiotics. This study is in the final stages of data analysis of anonymised follow-up via the SAIL databank.”

    Source location

    2019-0443-Response-from-the-Welsh-Ambulance-Services
    Page 3 · response
    Published 3 January 2020

    Open published response

    Source evidence

    How this respondent position was interpreted

    PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

    PFD Monitor interpretation

    The Trust will not provide routine pre-hospital antibiotics because evidence, training, equipment, costs and antimicrobial-resistance concerns constrain implementation.

    Verbatim wording from the response

    “Therefore, the current evidence base is not strong enough to demonstrate the benefits of out-of-hospital administration of antibiotics in sepsis by all paramedics, including time taken to train, the costs involved to purchase the additional medications and equipment, and maintain competency in the use of the drugs. In addition, controlled use of antibiotics is considered best practice to prevent antimicrobial resistance, which is on the increase.”

    Source location

    2019-0443-Response-from-the-Welsh-Ambulance-Services
    Page 3 · response
    Published 3 January 2020

    Open published response

    Source evidence

    How this respondent position was interpreted

    PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

    PFD Monitor interpretation

    Health Board Emergency Department staff are responsible for initiating antibiotics for patients delayed in ambulances because they prescribe and select appropriate treatment.

    Verbatim wording from the response

    “The Trust advocates that any administration of antibiotics for patients with red flag sepsis should be initiated within the Emergency Department and not in the back of an Emergency Ambulance. For patients held in the back of ambulances due to excessive”

    Source location

    2019-0443-Response-from-the-Welsh-Ambulance-Services
    Page 3 · response
    Published 3 January 2020

    Open published response
Back to top

Data last updated 7 September 2026